<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0361055</journal-id>
<journal-id journal-id-type="pubmed-jr-id">7770</journal-id>
<journal-id journal-id-type="nlm-ta">Toxicology</journal-id>
<journal-id journal-id-type="iso-abbrev">Toxicology</journal-id>
<journal-title-group>
<journal-title>Toxicology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0300-483X</issn>
<issn pub-type="epub">1879-3185</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26419632</article-id>
<article-id pub-id-type="pmc">4658258</article-id>
<article-id pub-id-type="doi">10.1016/j.tox.2015.09.005</article-id>
<article-id pub-id-type="manuscript">NIHMS730084</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Prenatal Drug Exposures Sensitize Noradrenergic Circuits to Subsequent Disruption by Chlorpyrifos</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Slotkin</surname>
<given-names>Theodore A.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Skavicus</surname>
<given-names>Samantha</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Seidler</surname>
<given-names>Frederic J.</given-names>
</name>
</contrib>
<aff id="A1">Department of Pharmacology &amp; Cancer Biology, Duke University Medical Center, Durham, North Carolina USA 27710</aff>
</contrib-group>
<author-notes>
<corresp id="FN1">Correspondence: Dr. T.A. Slotkin, Box 3813 DUMC, Duke Univ. Med. Ctr., Durham, NC 27710, Tel 919 681 8015, <email>t.slotkin@duke.edu</email></corresp>
<fn fn-type="conflict" id="FN2">
<p><bold>Conflict of interest statement</bold>: TAS has received consultant income in the past three years from the following firms: Acorda Therapeutics (Ardsley NY), Carter Law (Peoria IL), Pardieck Law (Seymour, IN), Tummel &amp; Casso (Edinburg, TX), and Chaperone Therapeutics (Research Triangle Park, NC).</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>16</day>
<month>10</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub">
<day>28</day>
<month>9</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="ppub">
<day>2</day>
<month>12</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>02</day>
<month>12</month>
<year>2016</year>
</pub-date>
<volume>338</volume>
<fpage>8</fpage>
<lpage>16</lpage>
<!--elocation-id from pubmed: 10.1016/j.tox.2015.09.005-->
<abstract>
<p id="P2">We examined whether nicotine or dexamethasone, common prenatal drug exposures, sensitize the developing brain to chlorpyrifos. We gave nicotine to pregnant rats throughout gestation at a dose (3 mg/kg/day) producing plasma levels typical of smokers; offspring were then given chlorpyrifos on postnatal days 1–4, at a dose (1 mg/kg) that produces minimally-detectable inhibition of brain cholinesterase activity. In a parallel study, we administered dexamethasone to pregnant rats on gestational days 17–19 at a standard therapeutic dose (0.2 mg/kg) used in the management of preterm labor, followed by postnatal chlorpyrifos. We evaluated cerebellar noradrenergic projections, a known target for each agent, and contrasted the effects with those in the cerebral cortex. Either drug augmented the effect of chlorpyrifos, evidenced by deficits in cerebellar β-adrenergic receptors; the receptor effects were not due to increased systemic toxicity or cholinesterase inhibition, nor to altered chlorpyrifos pharmacokinetics. Further, the deficits were not secondary adaptations to presynaptic hyperinnervation/hyperactivity, as there were significant deficits in presynaptic norepinephrine levels that would serve to augment the functional consequence of receptor deficits. The pretreatments also altered development of cerebrocortical noradrenergic circuits, but with a different overall pattern, reflecting the dissimilar developmental stages of the regions at the time of exposure. However, in each case the net effects represented a change in the developmental trajectory of noradrenergic circuits, rather than simply a continuation of an initial injury. Our results point to the ability of prenatal drug exposure to create a subpopulation with heightened vulnerability to environmental neurotoxicants.</p>
</abstract>
<kwd-group>
<kwd>Cerebellum</kwd>
<kwd>Chlorpyrifos</kwd>
<kwd>Dexamethasone</kwd>
<kwd>Nicotine</kwd>
<kwd>Norepinephrine</kwd>
<kwd>Organophosphate pesticides</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>